| 词条 | Pamrevlumab |
| 释义 |
| type = mab | image = | alt = | mab_type = | source = u | target = CTGF | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_UK = | legal_US = | legal_UN = | legal_NZ = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = | CAS_number = 946415-13-0 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | C = 6492 | H = 10018 | N = 1718 | O = 2086 | S = 48 | molecular_weight = 147.0 g/mol | UNII = QS5F6VTS0O | KEGG = D10969 | synonyms = FG-3019 | ChemSpiderID = none }} Pamrevlumab (INN[1]) (FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. This drug was developed by FibroGen, Inc.[2] References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113 | journal = WHO Drug Information | volume = 29 | issue = 2 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL113.pdf | format=PDF}} {{monoclonal-antibody-stub}}{{monoclonals for immune system}}2. ^[https://searchusan.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fpamrevlumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Pamrevlumab], American Medical Association. 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。